Hims Hers Health Inc (HIMS)vsJohnson & Johnson (JNJ)
HIMS
Hims Hers Health Inc
$30.56
+8.56%
HEALTHCARE · Cap: $6.78B
JNJ
Johnson & Johnson
$227.50
-1.37%
HEALTHCARE · Cap: $544.88B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 4005% more annual revenue ($96.36B vs $2.35B). JNJ leads profitability with a 21.8% profit margin vs 5.5%. HIMS appears more attractively valued with a PEG of 2.67. JNJ earns a higher WallStSmart Score of 59/100 (C).
HIMS
Hold50
out of 100
Grade: D+
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+24.9%
Fair Value
$39.63
Current Price
$30.56
$9.07 discount
Margin of Safety
-42.4%
Fair Value
$159.74
Current Price
$227.50
$67.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 25 in profit
Revenue surging 28.4% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 26.7%
Generating 1.5B in free cash flow
Areas to Watch
Trading at 12.8x book value
Distress zone — elevated risk
5.5% margin — thin
Operating margin of 2.7%
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Return on Equity, Revenue Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 26.7%.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Profit Margin. A P/E of 58.4x leaves little room for execution misses. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
HIMS profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.31 — expect wider price swings.
HIMS is growing revenue faster at 28.4% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 50/100), backed by strong 21.8% margins. HIMS offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?